Ligand Pharmaceuticals Incorporated (LGND) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Jupiter, CA, United States. Le PDG actuel est Todd C. Davis.
LGND a date d'introduction en bourse 1992-11-18, 68 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $4.63B.
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that develops and acquires innovative technologies to enable pharmaceutical companies to discover and develop medicines globally. The company maintains a diverse commercial portfolio spanning oncology, infectious disease, endocrinology, and other therapeutic areas, with key marketed products including Kyprolis and Evomela for multiple myeloma, Veklury for COVID-19, Vaxneuvance for pneumococcal disease prevention, and Zulresso for postpartum depression, among numerous others. Beyond its marketed medications, Ligand operates an extensive pipeline of partner and licensed programs in clinical development targeting cancer, seizure disorders, diabetes, cardiovascular disease, and other conditions. The company also supplies Captisol materials, a proprietary technology platform used in pharmaceutical formulations. Founded in 1987 and headquartered in Emeryville, California, Ligand serves as a strategic partner to the global pharmaceutical industry.
